newsfilter
← Latest News
GlobeNewswire·

Kaleido Biosciences Reports First Quarter 2021 Financial Results

--Positive results in patients with mild-to-moderate COVID-19 demonstrate KB109's potential to reduce healthcare utilization and recovery time; initiating IND application to support further development-- --Topline data from a clinical study of KB295 i